Hacettepe Uni’ 18 🎓Ankara Etlik City Hospital 📍🏥/Medical Oncology Fellow “ The Man With The Golden Stethoscope ”👨⚕️ | ASCO IDEA 2026 Awardee🏅
Ankara, Türkiye
Joined April 2010
- Tweets2.6K
- Following3K
- Followers880
- Likes10.2K
Enes Yeşilbaş retweeted
How Can Collaboration Shape the Future of Cancer Care? - Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO (@ASCOPres)
oncodaily.com/voices/elizabe…
Enes Yeşilbaş retweeted
🎗️Honored to be featured by @myESMO! Great to be at #ESMO26 in Madrid 🇪🇸, learning and connecting with colleagues and leaders from around the world 🌍
@myESMO
@BanerjeeSusana @HendriksLizza
@KlempnerSam @osutcuoglu @anacveneziani @uyargalip
#cancer #oncology – at Madrid, Spain
💬 “Every conversation at #ESMO26 can turn into a future project.”
Which conversations have had a lasting impact on your professional journey? Share your story using #ESMOconversations and #ESMO26.
Enes Yeşilbaş retweeted
Happy to share our new study published in The Oncologist!
In patients with de novo mHSPC, baseline 25(OH)D provided prognostic information for progression-free survival and contributed to a prognostic model that was externally validated.
🔗 doi.org/10.1093/oncolo/oyag3…
Grateful to all co-authors and collaborators.
#ProstateCancer #mHSPC #OncologyAdvances #Oncology
@osutcuoglu @kbaskurtt @Xesiloglu @drOrhunakdogan @tubaugurdr @yucelbirkadriye @oncodaily @OncoAlert @OncBrothers @OncoDailyGU @OUPAcademic
Enes Yeşilbaş retweeted
🚨 Can a routine pre-treatment blood test help predict pathological complete response (pCR) in breast cancer?
Thrilled to share our latest multi-center study now in #TheBreast
By combining lipid metabolism and systemic inflammation into a single marker, RCII (Remnant Cholesterol × CRP):
📉 Lower log-RCII was independently associated with a higher likelihood of pCR (adj. OR 0.48, 95% CI 0.33–0.69).
🎯 Strong discrimination in the external validation cohort (AUC: 0.84, 95% CI 0.76–0.91)!
A promising, accessible signal awaiting prospective validation 🔬
doi.org/10.1016/j.breast.202…
#BreastCancer #Oncology #MedTwitter #bcsm #OncologyAdvances
@osutcuoglu @kbaskurtt @Xesiloglu @drOrhunakdogan @oncodaily @OncoAlert @crisbergerot @DrMirallas @OncologyAdvance
Enes Yeşilbaş retweeted
Can Wearables Predict Post-Discharge Risk in Metastatic Cancer? - Galip Can Uyar (@uyargalip)
oncodaily.com/science/galip-…
Enes Yeşilbaş retweeted
⌚ Can a smartwatch identify high-risk patients after discharge?
In STEP-CANCER, ≤3,013 steps/day was linked to 90-day readmission (73% vs 13%) and mortality (47% vs 9%).
Congrats to @drOrhunakdogan , @uyargalip and team. Special thanks to @crisbergerot and @realbowtiedoc 🙏
Published! 🚀 Can wearables predict post-discharge risk in metastatic cancer? ⌚
Lower post-discharge mobility was associated with higher 90-day readmission & mortality.
Co-first w/ @drOrhunakdogan, with @crisbergerot @Realbowtiedoc @osutcuoglu @kbaskurtt @tubaugurdr @Xesiloglu
#DigitalOncology #Wearables #CancerCare #MedX #SupportiveCare
@ASCO @myESMO @oncodaily @OncoAlert @SuppCareCancer
doi.org/10.1007/s00520-026-1…
Enes Yeşilbaş retweeted
Congratulations @uyargalip !! 🎉 Great to see this work published @MASCC_JSCC!
Wearable-derived mobility as a potential marker of both clinical outcomes and PROs is such an important direction for supportive care
Thank you for including me
Enes Yeşilbaş retweeted
Published! 🚀 Can wearables predict post-discharge risk in metastatic cancer? ⌚
Lower post-discharge mobility was associated with higher 90-day readmission & mortality.
Co-first w/ @drOrhunakdogan, with @crisbergerot @Realbowtiedoc @osutcuoglu @kbaskurtt @tubaugurdr @Xesiloglu
#DigitalOncology #Wearables #CancerCare #MedX #SupportiveCare
@ASCO @myESMO @oncodaily @OncoAlert @SuppCareCancer
doi.org/10.1007/s00520-026-1…
Enes Yeşilbaş retweeted
🎉 Our new study is now published in Discover Oncology!
🧬 Association between PhenoAge-assessed biological age and survival outcomes in solid tumor patients treated with immune checkpoint inhibitors
🔬 In this retrospective, two-center study of 302 patients receiving immune checkpoint inhibitor monotherapy, we evaluated whether biological aging, assessed by PhenoAgeAccel, was associated with clinical outcomes.
📊 Patients with accelerated biological aging (PhenoAgeAccel >0) had significantly shorter PFS (3.8 vs 7.7 months)and OS (7.1 vs 20.4 months) compared with patients without accelerated biological aging.
💡 In multivariable analyses, PhenoAgeAccel remained independently associated with both PFS (HR 1.93) and OS (HR 2.19), suggesting that biological age may provide prognostic information beyond chronological age in patients receiving immunotherapy
Many thanks to @osutcuoglu for always guiding, supporting, and inspiring us, and to our amazing team for all their hard work and contributions.🙏🏻
📖 Discover Oncology
🔗 link.springer.com/article/10…
#Immunotherapy #BiologicalAge #PhenoAge #Immunosenescence #CancerResearch #Oncology #ImmuneCheckpointInhibitors
🎉🎉@DrOzanYazc1 @drOrhunakdogan @Xesiloglu @kbaskurtt @uyargalip
Enes Yeşilbaş retweeted
Topical Diclofenac for Preventing Capecitabine-Induced Hand-Foot Syndrome - Enes Yeşilbaş (@Xesiloglu)
oncodaily.com/science/enes-y…
Enes Yeşilbaş retweeted
Fantastic meeting these @ASCO LDP 2026-27 classmates at ASCO HQ , diversified group with amazing skills and leadership qualities! @FunchainMD @VaiaFlorou @Sarbaji85064063 @koshkin85 @gandhi_shipra and many others off twitter !
Enes Yeşilbaş retweeted
Still Lost in Transition? A 20-Year Reflection on Cancer Survivorship Care.
ascopubs.org/doi/10.1200/JCO…
@ASCO @JCO_ASCO @JCOOP_ASCO
#Survivorship #SuppOnc #CancerCare
Enes Yeşilbaş retweeted
Unforgettable Week at the ESO Multidisciplinary Masterclass - ENES YEŞİLBAŞ
@Xesiloglu @ESOncology
oncodaily.com/voices/enes-ye…
Enes Yeşilbaş retweeted
🧤🧦 Two surgical gloves + a compression stocking during paclitaxel infusion → significantly reduced moderate-to-severe CIPN in women with gynecologic cancers.
✍🏻Low-cost. Scalable. No pharmacology needed.
@Xesiloglu @uyargalip @osutcuoglu
💫 Special thanks to @CoquardRay and @dimeglio_anto for their invaluable support throughout this work.
Our new work NEURO-GLOVE Trial now published in @IJC_Wiley 👇🏻
Enes Yeşilbaş retweeted
From Mentorship to Manuscript: ASCO Virtual Town Hall on Building Academic Success for Early-Career Oncologists.
connection.asco.org/do/mento…
@ASCO @ASCOPost
#CancerResearch #MedEd #Mentorship
@thenasheffect @NazliDizman @saadnasir01
Enes Yeşilbaş retweeted
Mark you calendar now for #ASCOQLTY26!
asco.org/quality
Subscribe for meeting updates here:
app.smartsheet.com/b/form/f4…
@ASCO @fumikochino @crisbergerot
Enes Yeşilbaş retweeted
Fantastic having @Xesiloglu @PuplaRuth 2026 @ConquerCancerFd IDEA awardees from Turkey 🇹🇷 / Ethiopia 🇪🇹 attend @StephensonCC as part of the @ASCO IDEA program and talk about their home countries and journeys as individuals! @RyanNipp @TheDrWood @HMAbushukair
Enes Yeşilbaş retweeted
Great to meet @Xesiloglu again @ASCO and congratulations on all your achievements to date and wishing you continued success.
🎗️ ASCO26 Day 3
🎤 A day filled with inspiring plenary sessions and thought-provoking discussions at ASCO26.
🤝 It was a pleasure to meet Dr. @CliffordHudis, CEO of ASCO, and to connect with Dr. @fumikochino, whose work continues to highlight the importance of patient-centered outcomes in breast cancer care.
🌍 Meeting and exchanging ideas with outstanding colleagues such as @MGMcNamara and Dr. @ProfSyedHussain Hussain was equally rewarding and inspiring.
✨ From leadership and advocacy to innovation and collaboration, @ASCO continues to bring together the people shaping the future of cancer care.
🎗️ #ASCO26 #ASCO #IDEA2026 #ConquerCancer #GlobalOncology #CancerResearch #OncologyCommunity
@kbaskurtt
Enes Yeşilbaş retweeted
Many thanks @Xesiloglu . It was my pleasure to catch up and discuss future research ideas. @DrYukselUrun @DenizCanGuven1 @CliffordHudis @fumikochino @ASCO @ASCOPost
🎗️ ASCO26 Day 3
🎤 A day filled with inspiring plenary sessions and thought-provoking discussions at ASCO26.
🤝 It was a pleasure to meet Dr. @CliffordHudis, CEO of ASCO, and to connect with Dr. @fumikochino, whose work continues to highlight the importance of patient-centered outcomes in breast cancer care.
🌍 Meeting and exchanging ideas with outstanding colleagues such as @MGMcNamara and Dr. @ProfSyedHussain Hussain was equally rewarding and inspiring.
✨ From leadership and advocacy to innovation and collaboration, @ASCO continues to bring together the people shaping the future of cancer care.
🎗️ #ASCO26 #ASCO #IDEA2026 #ConquerCancer #GlobalOncology #CancerResearch #OncologyCommunity
@kbaskurtt
Enes Yeşilbaş retweeted
Not at #ASCO2026 in person this year, but proud to be there through science.
Grateful to contribute to four abstracts presented at the 2026 ASCO Annual Meeting, spanning supportive care, survivorship, symptom management, and real-world oncology research.
My sincere thanks to all mentors, collaborators, and co-authors who made these projects possible.
#ASCO26 #Oncology #CancerResearch #SupportiveCare #PalliativeCare #Survivorship #BreastCancer #RectalCancer
@osutcuoglu @kbaskurtt @Xesiloglu @drOrhunakdogan @crisbergerot @realbowtiedoc @ASCO @etliksehirhast @RyanNipp @oncodaily
